2-(4-butylphenyl)benzo[d]isothiazol-3(2H)-one | 35159-84-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 2-(4-butylphenyl)benzo[d]isothiazol-3(2H)-one
• 英文别名: 2-(4-butyl-phenyl)-benzo[d]isothiazol-3-one；2-(4-Butylphenyl)-1,2-benzothiazol-3-one
• CAS: 35159-84-3
• 化学式: C₁₇H₁₇NOS
• 分子量: 283.394
• InChiKey: NZFJGDSKVUKKGA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  45.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  硫代水杨酸 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 32.0h， 生成 2-(4-butylphenyl)benzo[d]isothiazol-3(2H)-one
  参考文献：
  名称：

  N取代的1,2-苯并异噻唑-3（2H）-酮对登革热病毒NS2BNS3蛋白酶的简便合成及其体外活性

  摘要：

  几种新的N-取代的1,2-苯并噻唑-3（2 H通过一种简便的合成途径合成了一个（BITs），以测试其抗登革热蛋白酶的抑制作用。与常规的多步合成相反，我们使用两步一锅法反应策略以优异的产率获得了结构多样的BIT。使用在线Swiss吸收，分布，代谢和消除（SwissADME）模型对所有合成的化合物进行了类药物特性的预筛选，表明它们具有良好的药物特性。因此，测试了合成的BITs对重组登革热病毒血清型2（DENV-2）NS2BNS3蛋白酶的抑制活性。剂量反应实验和计算机对接分析显示，一些BIT与IC 50催化三联体附近的蛋白酶结合值在微摩尔范围内。DENV2感染检测表明，两个BITs是2-（2-氯苯基）苯并[d]异噻唑-3（2 H）-一个和2-（2,6-二氯苯基）苯并[ d ]异噻唑-3（2 H）一，可以抑制DENV复制和病毒感染性。这些结果表明了BITs在开发新型抗登革热疗法中的潜力。

  DOI：

  10.3390/pathogens10040464

文献信息

• BENZOISOTHIAZOLONES AS INHIBITORS OF PHOSPHOMANNOSE ISOMERASE
  申请人：Cosford Nicholas D. P.

  公开号：US20110257233A1

  公开（公告）日：2011-10-20

  The disclosure provides new compounds and compositions thereof, and methods for treating or ameliorating a disorder relating to CDG-Ia. In particular, the disclosure provides benzoisothiazolone inhibitors of PMI, which have been synthesized and their ability to drive glycosylation has been demonstrated. The disclosure provides two synthetic routes for these compounds, including a new copper-catalyzed N-arylation reaction amenable to parallel derivitization. The disclosed compounds represent potent inhibitors of PMI, and their dose-dependent efficacy in cell-based models of glycosylation have been demonstrated. In addition, the disclosed compounds are selective over PMM and therefore, are useful in treating or ameliorating a disorder relating to CDG-Ia.
• [EN] BENZOISOTHIAZOLONES AS INHIBITORS OF PHOSPHOMANNOSE ISOMERASE<br/>[FR] BENZOISOTHIAZOLONES EN TANT QU'INHIBITEURS DE PHOSPHOMANNOSE ISOMÉRASE (PMI)
  申请人：SANFORD BURNHAM MED RES INST

  公开号：WO2011116355A2

  公开（公告）日：2011-09-22

  The disclosure provides new compounds and compositions thereof, and methods for treating or ameliorating a disorder relating to CDG-Ia. In particular, the disclosure provides benzoisothiazolone inhibitors of PMI, which have been synthesized and their ability to drive glycosylation has been demonstrated. The disclosure provides two synthetic routes for these compounds, including a new copper-catalyzed N-arylation reaction amenable to parallel derivitization. The disclosed compounds represent potent inhibitors of PMI, and their dose- dependent efficacy in cell-based models of glycosylation have been demonstrated. In addition, the disclosed compounds are selective over PMM and therefore, are useful in treating or ameliorating a disorder relating to CDG-Ia.